[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pasithea Therapeutics Corp WT (KTTAW)

Pasithea Therapeutics Corp WT (KTTAW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,430 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/13/26
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0041 +14.63%
on 06/29/26
0.0079 -40.51%
on 06/08/26
-0.0027 (-36.49%)
since 05/29/26
3-Month
0.0034 +38.24%
on 04/01/26
0.0191 -75.39%
on 04/02/26
-0.0066 (-58.41%)
since 03/27/26
52-Week
0.0034 +38.24%
on 04/01/26
0.1198 -96.08%
on 12/01/25
-0.0169 (-78.24%)
since 06/25/25

Most Recent Stories

More News
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

-- Remains on track to release interim NF1 data update in Q4 2026 -- -- Additional dose levels and longer treatment period added -- MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference

-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

MIAMI, April 20, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET – – Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Extends cash runway through at least the first half of 2028 Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments,...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Extends cash runway through at least the first half of 2028 Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron...

KTTA : 0.5261 (-3.18%)
KTTAW : 0.0047 (-28.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.